The urinary recovery of nitrofurantoin after a single 100-mg oral dose was studied in subjects with varying renal function. Almost all uremic patients excreted little or no drug in the urine during ...

In EAGLE-3, gepotidacin was statistically significantly superior to nitrofurantoin, with 58.9% (172/292) of patients having therapeutic success vs 44% (121/275) of patients on nitrofurantoin.

Currently, the most common treatment for uncomplicated UTIs in women is nitrofurantoin, an antibiotic that has been in use since the 1950s. Other options include trimethoprim-sulfamethoxazole and ...

As part of the research, scientists compared gepotidacin with nitrofurantoin, which is another common treatment for uUTIs (and bladder infections). The trials that evaluated gepotidacin involved ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs).

In one of GSK’s studies, gepotidacin achieved complete disease resolution in 58.5 per cent of patients compared with 43.6 per cent for nitrofurantoin. The drug’s development was partly funded ...

In EAGLE-2, Blujepa showed non-inferior therapeutic success compared to nitrofurantoin. In EAGLE-3, Blujepa demonstrated statistically significant superiority. Stay informed.

The FDA has approved Blujepa, a groundbreaking new antibiotic for treating uncomplicated urinary tract infections in women, marking the first new class of UTI medication in nearly three decades.

The primary endpoint of the studies was therapeutic response at test-of-cure (day 10–13) in patients with bacteria susceptible to nitrofurantoin. 1,2. EAGLE-2 confirmed that Blujepa was non-inferior ...

The Food and Drug Administration on Tuesday approved the first drug in a new class of antibiotics for treating urinary tract infections — the first time that’s happened in nearly 30 years ...